News | April 24, 2025
Thyrocare Technologies Q4 FY25 consolidated PAT up at Rs. 21.70 Cr
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The 27 greenfield labs across the country ensure timely and accurate reporting
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,
The supply of these goods is set to commence within the first quarter of FY26
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Subscribe To Our Newsletter & Stay Updated
